CAR-T cell(The First Affiliated Hospital of Zhengzhou University)

DUBLIN--( BUSINESS WIRE )--The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CAR T-cell Therapy was estimated at US$2.7 Billion in 2023 and is projected to reach US$10.8 Billion by 2030, growing at a CAGR of 21.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the CAR T-cell therapy market is driven by several factors, including technological advancements, expanding clinical indications, and the increasing demand for personalized cancer treatments. One of the primary drivers is the expanding body of clinical evidence demonstrating the efficacy of CAR T-cell therapy in treating various types of cancer, especially hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. The potential for CAR T-cell therapy to move into the treatment of solid tumors represents another key growth opportunity, as ongoing research continues to investigate new therapeutic targets and applications in cancers like lung, breast, and pancreatic cancer. Technological improvements in gene-editing tools and cell manufacturing processes are also contributing to the market's growth, allowing for faster and more cost-effective production of CAR T-cells. The increasing demand for personalized medicine is another crucial factor driving market expansion, as patients and healthcare providers look for treatments tailored to the unique genetic and molecular profile of individual cancers. This is especially important in cases where traditional therapies have failed, making CAR T-cell therapy a vital option for those with few alternatives. Additionally, the global rise in cancer prevalence is fueling demand for more innovative treatments, particularly in regions where regulatory approvals for CAR T-cell therapies are expanding, such as in Europe and Asia. The development of allogeneic CAR T-cell therapies, which could provide more affordable and widely available treatment options, further accelerates market growth. With continuous advancements in AI, which are improving treatment precision and monitoring, and the growing focus on enhancing patient outcomes, the CAR T-cell therapy market is positioned for robust growth in the years to come. What Are the Current Trends and Challenges in CAR T-Cell Therapy? Several important trends are shaping the future of CAR T-cell therapy, reflecting both its promise and the challenges that must be addressed to maximize its potential. One of the most exciting trends is the expansion of CAR T-cell therapy beyond blood cancers to solid tumors. Historically, treating solid tumors has been more complex due to the protective environment these tumors create around themselves, making it difficult for immune cells to penetrate and attack. However, research is actively exploring ways to enhance T-cell infiltration into solid tumors and sustain their activity in the hostile tumor microenvironment. Another significant trend is the development of allogeneic, or 'off-the-shelf,' CAR T-cell therapies. Unlike the traditional approach that requires extracting and modifying a patient's own cells (autologous therapy), allogeneic CAR T-cell therapy uses T-cells from healthy donors. This approach promises to significantly reduce the time and cost associated with the therapy, potentially making it more widely accessible. Despite these advancements, several challenges remain. Managing severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, remains a critical concern. These side effects occur when the immune system is over-activated by the therapy, causing inflammation and potentially dangerous complications. Research is focused on mitigating these risks, and several safety mechanisms, including built-in 'suicide switches' that deactivate the CAR T-cells in emergencies, are being developed. Additionally, the high cost of manufacturing CAR T-cell therapy, often exceeding several hundred thousand dollars per patient, is a major barrier to broader adoption. This cost reflects the complexity of producing a personalized, living cell therapy, but efforts to streamline production and develop more efficient manufacturing techniques are underway to reduce costs. Key Insights: Market Growth: Understand the significant growth trajectory of the DLBCL Indication segment, which is expected to reach US$5.1 Billion by 2030 with a CAGR of a 18.6%. The ALL Indication segment is also set to grow at 25.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, which was estimated at $761.0 Million in 2023, and China, forecasted to grow at an impressive 21.4% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as A2 Biotherapeutics, Inc., Adaptive Biotechnologies Corporation, Advanced Cell & Gene Therapy, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 179 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $2.7 Billion Forecasted Market Value (USD) by 2030 $10.8 Billion Compound Annual Growth Rate 21.9% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Incidence of Cancer Throws the Spotlight on CAR T-Cell Therapy as a Key Treatment Option Technological Advancements in Gene Editing Propel Growth in CAR T-Cell Therapy Efficacy and Safety Expanding Clinical Applications Beyond Blood Cancers Expands Addressable Market Opportunity Here`s How Personalized Medicine Strengthens the Business Case for CAR T-Cell Therapy Increased Research on Solid Tumor Applications Spurs Growth in CAR T-Cell Therapy Development Allogeneic `Off-the-Shelf` CAR T-Cell Therapies Generate New Opportunities in Manufacturing Emerging Strategies to Combat Cytokine Release Syndrome Expands the Safety Profile of CAR T-Cell Therapy Global Focus on Precision Oncology Expands the Market for CAR T-Cell Therapies FOCUS ON SELECT PLAYERS: (Total 12 Featured) A2 Biotherapeutics, Inc. Adaptive Biotechnologies Corporation Advanced Cell & Gene Therapy AffyImmune Therapeutics Allogene Therapeutics Beam Therapeutics CARsgen Therapeutics Celgene Corporation Cellular Biomedicine Group, Inc. Innovacell For more information about this report visit https://www.researchandmarkets.com/r/qghbj6 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

TUESDAY, Dec. 3, 2024 -- A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show. Aucatzyl (obecabtagene autoleucel) worked on more than three-quarters (76%) of patients with B-cell acute lymphoblastic leukemia (ALL), and more than half (55%) went into remission, according to results published recently in the New England Journal of Medicine . Based on these results, the U.S. Food and Drug Administration approved Aucatzyl for adults with this form of leukemia in November. “Patients with B-cell ALL need effective standalone treatment options, and [Aucatzyl] demonstrated strong long-term efficacy and response rates,” said lead U.S. investigator Dr. Elias Jabbour , a professor of leukemia with the University of Texas MD Anderson Cancer Center. This form of leukemia affects the development of B-cells, white blood cells made in the bone marrow that help the body fight off infections, according to the Leukemia Research Foundation. The cancer causes the bone marrow to churn out abnormal, immature B-cells called lymphoblasts. These abnormal B-cells build up in the bone marrow and spill over into the blood, causing them to quickly spread to other areas of the body. About 75% of adults with ALL have the B-cell ALL subtype, according to the LRF. Their five-year survival rate is around 40%. Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the immune system’s T-cells to detect cancer. The T-cells then trigger other parts of the immune system to seek and kill the cancer. With Aucatzyl, a person’s T-cells are taught to look for CD19, a protein commonly found on the surface of cancerous B-cells. For this study, researchers treated 127 adults who had either relapsed B-cell ALL or whose cancer was not responding to other therapies. All patients received chemotherapy to eliminate their existing T-cells, and then received Aucatzyl in two doses on days one and 10 of treatment. Among the 99 patients who responded to Aucatzyl, only 18 went on to require a stem cell transplant while in remission, results show. These transplants took place an average of 101 days after they were infused with the CAR T-cell therapy. There was no significant difference in survival between patients who got a stem cell transplant and those who didn’t, suggesting that Aucatzyl produces a long-lasting response, researchers said. Further, 68 high-risk patients achieved complete remission following their treatment. Of those, 58 patients had no cancer cells to be found in their blood. “Until now, these patients had limited treatment options,” Jabbour said in a MD Anderson news release. “We observed minimal immunotoxicity and a strong persistence of CAR T-cells, which support [Aucatzyl] being the standard of care for this population.” The study was funded by Aucatzyl’s developer, Autolus Therapeutics. Jabbour will present additional findings next week at the annual meeting of the American Society of Hematology. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.